Novavax, Fujifilm begin large-scale manufacturing of COVID-19 vaccine

By The Science Advisory Board staff writers

July 24, 2020 -- Novavax and Fujifilm Diosynth have signed an agreement covering the bulk manufacture of Novavax's COVID-19 vaccine candidate, NVX-CoV2373, at Fujifilm's Morrisville, NC, facility.

The large-scale manufacture of the vaccine candidate is part of the $1.6 billion award from the U.S. government's Operation Warp Speed. The award covers late-stage clinical development, including a phase III clinical trial and funds to establish large-scale manufacturing to enable the delivery of 100 million doses of the vaccine as early as late 2020.

Manufactured doses from the Fujifilm North Carolina site will be utilized in the phase III clinical trial of up to 30,000 subjects, which is expected to begin in the fall of 2020.

NVX-CoV2373 is a stable prefusion protein using Novavax's proprietary nanoparticle technology and adjuvant. Fujifilm will provide manufacturing capabilities and baculovirus expression system expertise to help deliver the 100 million doses.

$1.6B awarded to Novavax for COVID-19 vaccine
Novavax was awarded $1.6 billion by the U.S. government through Operation Warp Speed to deliver 100 million doses of a COVID-19 vaccine as early...
AGC to manufacture adjuvant for Novavax COVID-19 vaccine
AGC Biologics announced it is partnering with Novavax for large-scale good manufacturing practices production of critical components for Novavax's coronavirus...
Fujifilm Diosynth partners with Oxgene for gene therapy
Fujifilm Diosynth Biotechnologies has partnered with Oxgene to deliver gene therapy products with a 25% reduction in production time, the company reported...
Allterum, FujiFilm begin development, scale-up of monoclonal antibodies for leukemia
Allterum Therapeutics has received a $2.9 million product development grant from the Cancer Research and Prevention Institute of Texas to support...

Copyright © 2020 scienceboard.net


Conferences
Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter